Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + obinutuzumab versus FCR/BR in chronic lymphocytic leukemia
2019-003327-37Phase 3Active
- Sponsor
- Roche
- Start
- Dec 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of venetoclax, obinutuzumab, rituximab, bendamustine, cyclophosphamide and 1 more in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by Roche. Primary endpoint: MRD response rate in peripheral blood at Month 15. Started Dec 2019; status: active.
02
Drugs
venetoclaxobinutuzumabrituximabbendamustinecyclophosphamide
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2019-003327-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003327-37.